Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain

References

• Congdon N, Vingerling JR, Klein BE, et al. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol 2004;122:487-94
   PubMed Web of Science ®Google Scholar
• Williams A, Sloan FA, Lee PP. Longitudinal rates of cataract surgery. Arch Ophthalmol 2006;124:1308-14
   PubMed Web of Science ®Google Scholar
• Colin J. The role of NSAIDs in the management of postoperative ophthalmic inflammation. Drugs 2007;67:1291-308
   PubMed Web of Science ®Google Scholar
• Cho H, Wolf KJ, Wolf EJ. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol 2009;3:199-210
   PubMedGoogle Scholar
• Guex-Crosier Y. [Non-steroidal anti-inflammatory drugs and ocular inflammation]. Klin Monbl Augenheilkd 2001;218:305-8
   PubMed Web of Science ®Google Scholar
• Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Survey of ophthalmology 2010;55:108-33
   PubMed Web of Science ®Google Scholar
• Friedlaender MH. Corticosteroid therapy of ocular inflammation. Int Ophthalmol Clin 1983;23:175-82
   PubMedGoogle Scholar
• Roberts CW, Brennan KM. A comparison of topical diclofenac with prednisolone for postcataract inflammation. Arch Ophthalmol 1995;113:725-7
   PubMed Web of Science ®Google Scholar
• ISTA Pharmaceuticals, Inc. Xibrom (bromfenac ophthalmic solution) 0.09% Package Insert, 2010
   Google Scholar
• Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963;70:482-91
   PubMed Web of Science ®Google Scholar
• Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol 2000;27:558-62
   PubMed Web of Science ®Google Scholar
• Donnenfeld ED, Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin 2006;46:21-40
   PubMedGoogle Scholar
• Donnenfeld ED, Holland EJ, Stewart RH, et al. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 2007;114:1653-62
   PubMed Web of Science ®Google Scholar
• Stewart RH, Grillone LR, Shiffman ML, et al. The systemic safety of bromfenac ophthalmic solution 0.09%. J Ocul Pharmacol Ther 2007;23:601-12
   PubMed Web of Science ®Google Scholar
• Walsh DA, Moran HW, Shamblee DA, et al. Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues. J Med Chem 1984;27:1379-88
   PubMed Web of Science ®Google Scholar
• Smyth EMBA, FitzGerald GA. Lipid-Derived Autacoids: Eicosanoids and Platelet-Activating Factor, 11th edn. New York, NY: McGraw-Hill, 2006
   Google Scholar
• Kida T, Ogawa T, McNamara TR, et al. Evaluations of the human COX-2 inhibition for amfenac, bromfenac, diclofenac, and ketorolac. 33rd Symposium on Cataract, IOL, and Refractive Surgery of the American Society of Cataract and Refractive Surgery, April 27–May 1, 2007, San Diego, CA, USA
   Google Scholar
• Co SP. Bronuck Ophthalmic Solution 0.1% Package Insert. Osaka, Japan, 2009
   Google Scholar
• ISTA Pharmaceuticals Inc. Data on file
   Google Scholar
• Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 2005;112:953-61
   PubMed Web of Science ®Google Scholar
• Ikeda H, Sato M, Tsukamoto H, et al. [Evaluation and multivariate statistical analysis of factors influencing patient adherence to ophthalmic solutions]. Yakugaku Zasshi 2001;121:799-806
   PubMed Web of Science ®Google Scholar
• Baklayan GA, Patterson HM, Song CK, et al. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther 2008;24:392-8
   PubMed Web of Science ®Google Scholar
• Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007;144:533-40
   PubMed Web of Science ®Google Scholar
• Cha SH, Lee JS, Oum BS, et al. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Experiment Ophthalmol 2004;32:180-4
   PubMed Web of Science ®Google Scholar
• Alcon Laboratories. Nevanac (nepafenac ophthalmic suspension) 0.1% Package Insert. Fort Worth, TX, USA, 2008
   Google Scholar
• Allergan, Inc. Acuvail (ketorolac tromethamine ophthalmic solution) 0.45% Package insert, Irvine, CA, USA, 2009
   Google Scholar
• ISTA Pharmaceuticals, Inc. Bromday (bromfenac ophthalmic solution) 0.09% Package Insert. Irvine, CA, USA, 2010
   Google Scholar